DIABETES PREVENTION PROGRAM

糖尿病预防计划

• 批准号: 6304231
• 负责人: RICHARD F HAMMAN
• 金额: $ 3.22万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304231
• 关键词: blood glucose; body physical activity; cardiovascular disorder prevention; clinical research; diabetes mellitus therapy; disease /disorder prevention /control; disease /disorder proneness /risk; glucose tolerance; human subject; human therapy evaluation; insulin sensitivity /resistance; noninsulin dependent diabetes mellitus; nutrient intake activity; nutrition related tag; obesity; prediabetic state; therapy compliance

The principal objective of the DPP is to prevent or delay the development of NIDDM in those persons who are at high risk for its development by virtue of having impaired glucose tolerance. Impaired glucose tolerance represents a less severe stage of blood glucose abnormalities that often precedes NIDDDM. The primary outcome is the development of diabetes according to American Diabetes Association criteria (fasting plasma glucose level > 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose > 200 mg/dL [11.1 mmol/L]), after a 75 gram OGTT, and confirmed with a repeat test). Secondary outcomes will focus on cardiovascular disease and its risk factors and changes in glycemia, insulin secretion and sensitivity, obesity, physical activity and nutrient intake, and the occurrence of adverse events. For the primary outcome time to development of diabetes, product-limit life-table distributions of each intervention group and the control group will be compared using the log-rank test statistic. The primary analyses will include all participants in their randomly assigned treatment group, regardless of adherence to the assigned treatment (intention-to-treat principle).

DPP的主要目的是防止或延迟那些因葡萄糖耐受性受损而面临高风险发展的人的NIDDM的发展。 葡萄糖耐受性受损代表了血糖异常的严重阶段，通常是在NIDDDM之前。主要结果是根据美国糖尿病关联标准（禁食等离子体葡萄糖水平> 126 mg/dl [7.0 mmol/l]或2小时血浆葡萄糖> 200 mg/dl [11.1 mmol/l]），糖尿病的发展75克OGTT，并通过重复测试确认）。 次要结果将集中于心血管疾病及其危险因素以及血糖，胰岛素分泌和敏感性，肥胖，体育活动和营养摄入量以及不良事件的发生。对于糖尿病发展的主要结果，将使用对数秩检验统计量比较每个干预组和对照组的产品限制生命表分布。 主要分析将包括其随机分配的治疗组中的所有参与者，无论遵守指定的治疗方法如何（意向性治疗原则）。